title: Corrigendum to 'Demographic and Clinical Characteristics of Type 2 Diabetes Mellitus Patients Initiating Dipeptidyl Peptidase-4 Inhibitors - A Retrospective Study of UK General Practice' Clin Ther 2016;8:1825-1832.e15.
authors.affiliation: Boehringer Ingelheim Ltd, Berkshire, United Kingdom. Electronic address: abby.tebboth@boehringer-ingelheim.com.
authors.forename: Abigail
authors.initials: A
authors.lastname: Tebboth
authors.affiliation: Boehringer Ingelheim Ltd, Berkshire, United Kingdom.
authors.forename: Sally
authors.initials: S
authors.lastname: Lee
authors.affiliation: Boehringer Ingelheim Ltd, Berkshire, United Kingdom.
authors.forename: Anna
authors.initials: A
authors.lastname: Scowcroft
authors.affiliation: Boehringer Ingelheim Ltd, Berkshire, United Kingdom.
authors.forename: Paula
authors.initials: P
authors.lastname: Bingham-Gardiner
authors.affiliation: Boehringer Ingelheim Ltd, Berkshire, United Kingdom.
authors.forename: William
authors.initials: W
authors.lastname: Spencer
authors.affiliation: Eli Lilly and Company, Basingstoke, United Kingdom.
authors.forename: John
authors.initials: J
authors.lastname: Bolodeoku
authors.affiliation: Eli Lilly and Company, Basingstoke, United Kingdom.
authors.forename: Syed Wasi
authors.initials: SW
authors.lastname: Hassan